Mitozolomide

Mitozolomide

Clinical data
ATC code	none
Identifiers
IUPAC name 3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
CAS Number	85622-95-3  Y
PubChem CID	71766
ChemSpider	64805  N
UNII	E3U7286V3W
ChEMBL	ChEMBL435951  N
CompTox Dashboard (EPA)	DTXSID40234862
ECHA InfoCard	100.079.921
Chemical and physical data
Formula	C7H7ClN6O2
Molar mass	242.62 g·mol−1
3D model (JSmol)	Interactive image
SMILES NC(=O)c1ncn2C(=O)N(CCCl)\N=N/c12
InChI InChI=1S/C7H7ClN6O2/c8-1-2-14-7(16)13-3-10-4(5(9)15)6(13)11-12-14/h3H,1-2H2,(H2,9,15) N Key:QXYYYPFGTSJXNS-UHFFFAOYSA-N N
NY  (what is this?)    (verify)

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression. ^[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide. ^[2]

References

1. Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA (February 2000). "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide" (PDF). Cancer Gene Ther. 7 (2): 233–9. doi: 10.1038/sj.cgt.7700120 . PMID   10770631. S2CID   2597751.
2. Newlands ES, Blackledge GR, Slack JA, et al. (February 1992). "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)". Br J Cancer. 65 (2): 287–91. doi:10.1038/bjc.1992.57. PMC   1977719 . PMID   1739631.